Emblem Corp (EMC), the Healthcare company, was revisited by a Wall Street analyst on November 21. Analyst Martin Landry from GMP FirstEnergy rated Emblem Corp (EMC) a Buy on November 21, setting a C$2.75 price target.
According to TipRanks.com, Landry is ranked #19 out of 5129 analysts.
Read also: Does Amarin’s (AMRN) Impending FDA Decision Matter?
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emblem Corp with a C$3.38 average price target.
The company has a one-year high of C$2.76 and a one-year low of C$1.08. Currently, Emblem Corp has an average volume of 886.5K.
Emblem Corp. engages in the sale of cannabis to patients who have received medical authorizations to acquire and use such cannabis. Its activities include production and sale of dried cannabis to qualified patients. The Company was founded on February 25, 2008 and is headquartered in Toronto, Canada.
The company’s shares closed on Monday at C$1.22, close to its 52-week low of C$1.08.
